Reaction
Pancreatic Cyst reporting signals
As of the last recalculation, Pancreatic Cyst appears in 1,874 FAERS reports alongside 29 co-occurring drug terms. The strongest observed disproportionality signal is PANCRELIPASE (PRR 42.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pancrelipase | 138 | 42.8 | 42.9 |
| Carboxymethylcellulose Sodium | 16 | 19.1 | 19.1 |
| Teduglutide | 21 | 17.5 | 17.5 |
| Sitagliptin And Metformin Hydrochloride | 29 | 15.2 | 15.2 |
| Ampicillin | 10 | 13.5 | 13.5 |
| Ampicillin Sodium | 10 | 13.5 | 13.5 |
| Dicyclomine Hydrochloride | 15 | 11.8 | 11.8 |
| Sitagliptin | 72 | 11.5 | 11.5 |
| Epoprostenol | 13 | 11.1 | 11.1 |
| Liraglutide | 47 | 10.8 | 10.8 |
| Lanreotide Acetate | 7 | 9.9 | 10.0 |
| Minocycline | 10 | 9.6 | 9.6 |
| Isosorbide Dinitrate | 16 | 9.2 | 9.2 |
| Mometasone | 15 | 9.1 | 9.2 |
| Pegaspargase | 9 | 8.2 | 8.2 |
| Exenatide | 37 | 7.9 | 8.0 |
| Ursosiol | 13 | 7.5 | 7.5 |
| Instalax Polyethylene Glycol 3350 | 8 | 7.2 | 7.2 |
| Ursodiol | 14 | 7.2 | 7.2 |
| Polyethylene Glycol 400 | 8 | 7.0 | 7.0 |
| Oral Semaglutide | 41 | 6.3 | 6.3 |
| Riociguat | 14 | 4.8 | 4.8 |
| Insulin Lispro | 58 | 4.8 | 4.8 |
| Lumacaftor And Ivacaftor | 3 | 3.9 | 3.9 |
| Sevelamer Carbonate | 4 | 3.9 | 3.9 |
| Elexacaftor, Tezacaftor, And Ivacaftor | 4 | 3.6 | 3.6 |
| Dulaglutide | 22 | 2.8 | 2.8 |
| Tirzepatide | 38 | 2.6 | 2.6 |
| Relugolix | 5 | 2.4 | 2.4 |